Infusion Rate and Volume Kinetics for Hyperoncotic Albumine in Healthy Subjects ((RAV))
Treatment with colloidal solutions has during long time been a cornerstone within intensive care. Lately there has been a shift from synthetic colloids to natural albumine.
One of these solutions is the hyperoncotic "Albumin 20%". There are however still several aspects of the physiological effects of hyperoncotic albumin, that are not known.
In this study the main object is to study with what rate hyperoncotic albumin should be administered. Rapidly 30 minutes or slower 120 minutes.
Studieöversikt
Detaljerad beskrivning
Difference in volume expansion as well as fluid recruitment from the tissues depending on infusion rate is of interest.
Plasma volume expansion is measured using hemoglobin as a marker and fluid recruitment of tissue fluid is measured as a combination of plasma volume expansion and urinary output.
Healthy individuals are asked to refrain from eating and drinking the night before the study. Two hours before study start, the subjects may take a sandwich and a glas to drink.
After 15 minutes of rest baseline blood samples are taken. Subjects are randomised to receive two rates of albumin solution (Albumin 20%) 3 ml/kg bodyweight at two separate occasions. Once with an infusion time of 30 minutes, once with an infusion time of 120 minutes. Between the two infusions there will be an interval of 3 to 20 weeks. Randomization is performed to chose which rate the subjects start with. 6 in each Group (total 12).
During each occasion15 blood samples are collected, during a 6 hour period. Hemoglobin, plasma Sodium, colloid osmotic pressure and albumin are analysed. The total volume of blood collected will be 170 ml at each occasion when an albumin infusion is given.
Urinary output is measured and Urinary Sodium content is measured. Liberal fluid intake is recommended the same day and the next.
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 4
Kontakter och platser
Studieorter
-
-
-
Linköping, Sverige
- Intensive Care Unit, University Hospital
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Healthy, without allergies and with the age 18 years or above
Exclusion Criteria:
- Heart failure
- Signs of kidney injury/failure
- Severe allergies
- Pregnancy
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Crossover tilldelning
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Rapid - Slow
Two infusions of 3 ml/kg bodyweight of hyperoncotic albumin 20%, with an interval of 3 to 20 weeks between. First time rapid (30 minutes), second time slow (120 minutes). Albumin solution |
Infusion rate and effects
|
|
Experimentell: Slow - Rapid
Two infusions of 3 ml/kg bodyweight of hyperoncotic albumin 20%, with an interval of 3 to 20 weeks between. First time rapid (120 minutes), second time slow (30 minutes). Albumin solution |
Infusion rate and effects
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Plasma volume
Tidsram: 6 hours
|
Albumin infusion expands the plasma volume and dilutes hemoglobin.
The dilution of hemoglobin can be measured and is used to calculate the degree of plasma expansion.
|
6 hours
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Colloid osmotic pressure
Tidsram: 6 hours
|
Infusion of hyperoncotic albumin increases the colloid osmotic pressure of plasma.
Fluid recruitment from the tissues however diminishes the increase of the colloid osmotic pressure.
This effect is measured.
|
6 hours
|
|
Fluid recruitment from tissues
Tidsram: 6 hours
|
The recruitment of fluid from the tissues due to the increase of colloid osmotic pressure is measured.
The total recruitment of fluid from the tissues is the sum of the plasma volume dilution and urinary excretion.
|
6 hours
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Joachim Zdolsek, MD, PhD,Assoc prof, University Hospital, Linkoeping
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Andra studie-ID-nummer
- RAV
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Ödem Sekundär
-
National Cancer Institute, EgyptAvslutadBenneoplasma, elakartad vertebral Column Thoracic SecondaryEgypten
Kliniska prövningar på Albumin solution
-
University of Roma La SapienzaAvslutad
-
Medical University of GrazAvslutadDekompenserad cirrosÖsterrike
-
Baylor College of MedicineAvslutadSubaraknoidal blödningFörenta staterna
-
Bausch & Lomb IncorporatedAvslutadSkadliga effekter av kontaktlinslösningMalaysia
-
Hainan People's HospitalSouthern Medical University, ChinaOkänd
-
Institute of Liver and Biliary Sciences, IndiaAvslutadSpontan bakteriell peritonitIndien
-
University of California, San DiegoGrifols Biologicals, LLCAvslutadVätskeöverbelastning | Hypotoni under dialys
-
National Medical Research Center for Rehabilitation...Pirogov Russian National Research Medical University; DNKOM LLC; The Orenburg...RekryteringHjärt-kärlsjukdomar | Sjukdomar i nervsystemet | Urologiska sjukdomar | Diabetes | Neuromuskulära sjukdomar | Hyperkolesterolemi | Gikt | Hyperbilirubinemi | Hyper IgE syndrom | Hyper-LDL-kolesterolemi | Hyper Beta Lipoproteinemia | Hyper eosinofilt syndromRyska Federationen
-
Vanderbilt University Medical CenterAvslutadHjärtsjukdomarFörenta staterna
-
Technical University of MunichAvslutad